City Clinical Hospital No 40

Moscow, Russia

City Clinical Hospital No 40

Moscow, Russia
SEARCH FILTERS
Time filter
Source Type

Filonenko E.V.,Moscow State University | Kaprin A.D.,National Medical Research Radiological Center | Alekseev B.Y.,National Medical Research Radiological Center | Ivanova-Radkevich V.I.,Peoples' Friendship University of Russia | And 3 more authors.
Biomedical Photonics | Year: 2017

The results of multicenter trial for efficacy of fluorescence diagnosis for bladder cancer with agent hexasens (SSC Scientific Research Institute Organic Intermediates and Dyes, Russia) based on hexyl ester of 5-aminolevulinic acid compared with routine cystoscopy are represented in the article. The study included 124 patients. All patients had intravesical instillation of 50 ml of 0,2% hexasens. The exposure time accounted for 1-2 h. After removal of the drug from bladder standard cystoscopy followed by fluorescence diagnosis was performed in every patient. During the local fluorescence spectroscopy the intravesical instillation of the agent hexasens was shown to induce selective accumulation of photoactive protoporphyrin IX in tumor cells comparing with intact bladder mucosa. During 1 h after intravesical instillation of hexasens solution the level of fluorescence of hexasens-induced protoporphyrin IX in the tumor was higher than that in surrounding intact mucosa at average in 5.8 fold. As compared with results of standard cystoscopy, fluorescence diagnosis improved the sensitivity of the method by 24.4% (from 75.6% to 100%), the accuracy - by 15.2% (from 83.3% to 98.5%) and negative predictive value - by 33.5% (from 66.5% to 100%). Fluorescence diagnosis gave an opportunity to detect additional tumor foci, which were invisible in white light, in 27.4% of patients. For fluorescence diagnosis in 4.0% of patients false-positive fluorescence of bladder mucosa was detected that was probably due to inflammation. None of patients received active dose of the drug hexasens had adverse reactions, changes in general well-being and blood and urine parameters. According to the results of the study fluorescence diagnosis with hexasens for bladder cancer is recommended for use in clinical practice.


Ter-Ovanesov M.D.,Russian National Research Medical University | Fatuev O.E.,City Clinical Hospital No 40 | Aksarin A.A.,Regional Oncology Dispensary | Baksiyan G.A.,City Clinical Hospital No 40 | And 3 more authors.
Voprosy Onkologii | Year: 2015

Patients with resectable non-small cell lung cancer have a chance to reach a 5-year survival rates ranging from 70% or more for stage IA and 20% for stage IIIA. These figures have remained stable for the past 20 years. Moreover, the inability to improve long-term outcomes is generally determined by a fatal disease progression due to the emergence of distant metastases or local recurrence often in combination with systemic progression process. Thus the use of chemotherapy both in neoadjuvant and adjuvant regimens has stimulated for a long time the search for the optimal scheme and treatment options. This article presents a critical analysis of the current state of the problem of neoadjuvant and adjuvant chemotherapy as well as chemoradiotherapy in order to optimize the tactics of combined treatment of these groups of patients.


Ter-Ovanesov M.D.,Russian National Research Medical University | Fatuev O.E.,City Clinical Hospital No 40 | Gaboyan A.S.,City Clinical Hospital No 40 | Levitsky A.V.,City Clinical Hospital No 40 | And 3 more authors.
Voprosy Onkologii | Year: 2015

Despite the modern achievements of different methods of treatment, primarily surgical, with recognized need of standardization of lymphadenectomy D2, gastric cancer still remains one of the most difficult malignant tumors characterized by high rates of one-year mortality and low rates of survival that are far from satisfactory. According to experts such unsatisfactory results are determined by a combination of factors: the characteristics of ill people, their functional status, age characteristics, the prevalence of the disease at diagnosis with the presence of systemic micrometastases, resistance to treatment, etc. Moreover, a factor of resistance to treatment i.e. to existing schemes and methods is mostly a key one that determines low levels of long-term survival.

Loading City Clinical Hospital No 40 collaborators
Loading City Clinical Hospital No 40 collaborators